quartr
Clarity Pharmaceuticals: SAR-bisPSMA delivers superior prostate cancer detection and clinical impact, driving market differentiation
Corrected summary: SAR-bisPSMA, an Australian-developed radiopharmaceutical, shows superior lesion detection, higher tumour uptake, and greater clinical impact than current PSMA PET agents. Supported by strong evidence, it offers flexible imaging, a favourable safety profile, and targets a multi-bi…